focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Share News (ETX)

  • There is currently no data for ETX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS: Riverstone Credit stays stable, Bloomsbury hails record half

Thu, 26th Oct 2023 18:12

(Alliance News) - The following is a round-up of earnings updates by London-listed companies, issued on Wednesday and Thursday, and not separately reported by Alliance News:

----------

Riverstone Credit Opportunities Income PLC - London-based energy infrastructure and energy transition credit investor - Net asset value at September 30 was USD1.07, unchanged from June 30. Says this stability was due to continued strong portfolio performance during the third quarter of 2023, and that as of September 30 it is nearly fully invested based on the revolving credit facility added in the fourth quarter last year and on current portfolio commitments. Riverstone Credit says it remains extremely well positioned due to its portfolio of accredited energy-transition focused investments through green or sustainability-linked structured loans. Notes "backdrop of strong energy market performance, the global focus on decarbonisation and the company's unique focus on short duration lending."

----------

Bloomsbury Publishing PLC - London-based publisher - Pretax profit for the half year ended August 31 was up 8% to GBP14.0 million from GBP12.9 million the year before. Says revenue increased 11% to GBP136.7 million from GBP122.9 million, and diluted earnings per share rose 11% to 13.66 pence from 12.30p. Consumer revenue grew 17% to GBP89.4 million, Adult Trade revenue rose 8% to GBP27.6 million and Children's Trade revenue grew 22% to GBP61.7 million. Declares interim dividend of 3.70p per share, more than double 1.41p the prior year. Cash at August 31 totalled GBP39.1 million, down from GBP41.5 million on the same day in 2022. Says it is confident it will achieve market expectations for the year ending February 29 2024, meaning revenue of GBP273.1 million and profit before tax and "highlighted items" of GBP32.5 million.

----------

Schroder Income Growth Fund PLC - UK-based investment company - Lifts dividend for the year ended August 31 by 4.6% to 13.80p per share from 13.20p the year before. Net asset value total return was positive 4.2%, underperforming against positive 5.2% from the FTSE All Share Total Return index. NAV per share decreased to 293.58p from 295.26p. Says many challenges "look set to continue into the year ahead."

----------

Haydale Graphene Industries PLC - Carmarthenshire, Wales-based technology solutions company - Pretax loss for the year ended June 30 widens to GBP6.6 million compared with GBP5.2 million the previous year. Revenue increased 48% to GBP4.3 million from GBP2.9 million, with US sales continuing to progress on "growth in the core aerospace and automotive markets". Administrative expenses increased 13% to GBP6.3 million from GBP5.5 million. Non-Executive Chair David Banks says: "We have made important progress in our next planned steps as a business by forging commercial partnerships and collaborations with leading organisations...the board remains confident that the company will be able to take advantage of the traction it is now seeing."

----------

e-Therapeutics PLC - Oxford, England-based computer-based drug discovery company - Says that in six months ended July 31, pretax loss widened to GBP6.6 million from GBP4.5 million the previous year. Revenue fell 46% to GBP160,000 from GBP295,000. Chief Executive Officer Ali Mortazavi says: "Despite a severe macroeconomic climate, we have made significant progress during the past six months...we have been able to translate our computational analyses into tangible assets, generating compelling preclinical data at a fraction of the R&D spend of any competitor." Research & development expenditure increased to GBP5.3 million from GBP3.1 million. Company expects higher "underlying cash burn" in the current half year due to its "planned increase in R&D spend to continue the expansion of our AI capabilities and progress the identification and execution of preclinical targets, together with sustaining our active IP strategy as novel inventions are generated."

----------

By Emma Curzon, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
29 Oct 2019 18:49

Invesco's Holding In e-Therapeutics Drops To Zero From 32%

Invesco's Holding In e-Therapeutics Drops To Zero From 32%

Read more
7 Oct 2019 09:14

e-therapeutics Loss Narrows On Lower Costs, Collaboration Income

e-therapeutics Loss Narrows On Lower Costs, Collaboration Income

Read more
7 Oct 2019 09:13

e-therapeutics Loss Narrows On Lower Costs, New Collaboration Income

e-therapeutics Loss Narrows On Lower Costs, New Collaboration Income

Read more
13 Aug 2019 12:16

e-Therapeutics Partners With Pharma Firm For Drug Discovery

(Alliance News) - e-Therapeutics PLC on Tuesday said it has agreed to work with an undisclosed global pharmaceutical company, on a project in a specific area of biology, associated with occurs is

Read more
10 Jun 2019 13:33

Woodford Raises GBP500 Million From Flurry Of London Share Sales (ALLISS)

LONDON (Alliance News) - Over the past week, fund manager Neil Woodford's Woodford Investment Management has conducted a fire sale of its stakes in 20 London-listed companies - raising in of -

Read more
5 Mar 2019 11:50

e-Therapeutics Annual Loss Narrows Amid Reduced Research Costs

LONDON (Alliance News) - e-Therapeutics PLC on Tuesday said its annual loss narrowed as research and development costs were significantly cut.For the year ended January, the drug discovery

Read more
26 Feb 2019 16:08

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 27 February ITVFull Year ResultsRio TintoFull Year Results (at 0600 James's

Read more
10 Dec 2018 14:30

E-Therapeutics launches research collaboration with Novo Nordisk

(Sharecast News) - E-Therapeutics announced a research collaboration with Novo Nordisk on Monday, under which the two companies would use e-Therapeutics' proprietary 'Network-Driven Drug Discovery' (NDD) platform to look to discover potentially novel biological mechanisms and therapeutic approaches for a specific area of type-2 diabetes.

Read more
6 Dec 2018 16:04

E-Therapeutics and C4X upbeat on Parkinson's collaboration

(Sharecast News) - Network-driven drug discovery company e-Therapeutics and C4X Discovery Holdings updated the market on their collaboration on Thursday, to identify novel intervention strategies for the potential treatment of Parkinson's Disease (PD).

Read more
6 Dec 2018 09:23

e-Therapeutics And C4X Identify New Pathways For Parkinson's Treatment

LONDON (Alliance News) - C4X Discovery Holdings PLC and e-Therapeutics PLC on Thursday said that, through their collaboration, they discovered additional novel biological pathways for the of that

Read more
4 Oct 2018 11:08

e-Therapeutics narrows interim losses as it eyes commercial viability

(Sharecast News) - Half-year losses at e-Therapeutics have narrowed as the drug discovery and development firm continued to manage costs.

Read more
4 Oct 2018 10:31

e-Therapeutics Interim Loss Narrows As It "Carefully" Manages Costs

LONDON (Alliance News) - e-Therapeutics PLC said Thursday that its half-year loss narrowed as it continued to effectively and "carefully" manage its costs.For the six months ended

Read more
27 Sep 2018 16:16

UK Earnings, Trading Statements Calendar - Next 7 Days

Friday 28 September United UtilitiesTrading Statement Baillie Gifford Shin Year 1 events 2 3

Read more
24 May 2018 16:10

UK Shareholder Meetings Calendar - Next 7 Days

Friday 25 MayHochschild MiningFerrexpoKeywords Mutual (re managed 28 events 29 Stobart Life (re of

Read more
1 May 2018 11:41

e-Therapeutics Pens Research Collaboration With C4X Discovery

LONDON (Alliance News) - e-Therapeutics PLC and C4X Discovery Holdings PLC on Tuesday announced a research collaboration to look into insights into Parkinson's disease.The partnership,

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.